Cinnarizine Tablets
Case reference FOI2025/00610
Received 22 June 2025
Published 12 August 2025
Request
I am writing under the provisions of the Freedom of Information Act 2000 to request information held by the Medicines and Healthcare products Regulatory Agency (MHRA) concerning the marketing authorisations of the following pharmaceutical products: Product MAH PL Stugeron 15mg Tablets Janssen-Cilag/McNeil PL 15513/0349 Cinnarizine 15mg Tablets Mylan PL 04569/0476 PL 04569/0599 Specifically, I am requesting the release of non-confidential regulatory and technical information available within the marketing authorisation dossiers, as detailed below: Source of information Current Information required Module 2 All sections of this Module - From 2.5 to 2.7.6 I acknowledge that certain parts of this information may fall under exemptions per Sections 41 (Information provided in confidence) or 43 (Commercial interests) of the Freedom of Information Act.
Response
see attached
Documents
This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.
You can browse our other responses or make a new FOI request.